

Preclinical study of VRN08, an oral Mps1 inhibitor to modulate SAC for advanced solid tumor

Voronoi, Inc.



ONCOLOGY	Non-Clinical
Product Type	Small Molecule (Kinase inhibitor)
Indication	Advanced solid tumor
Target	Monopolar Spindle 1 (Mps1/TTK)
MoA(Mechanism of Action)	Inhibition of Mps1 promotes apoptosis of cancer cells by inducing mitotic catastrophe
Competitiveness	First in class TreadWell Therapeutics' CFI-402257 is under Ph2 clinical development stage. VRN08 is more potent and higher exposure in tumor than CFI-402257.
Development Stage	Non-Clinical
Route of Administration	Oral